|View printer-friendly version|
|Illumina Launches the VeriSeq™ NIPT Solution in Europe|
NGS-based Solution Makes Fast, Highly Accurate, Cost-effective
Noninvasive Prenatal Testing Available to
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170409005007/en/
VeriSeq™ NIPT Solution (Photo: Business Wire)
The VeriSeq™ NIPT Solution provides accurate information about fetal chromosome status as early as 10 weeks gestation using a single maternal blood draw. This noninvasive screen yields results for trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome), as well as certain sex chromosome-related disorders. Due to its high-sensitivity and high-specificity (low false-positive and false-negative rates), NGS-based NIPT minimizes the need for invasive testing procedures.
"As a proud partner of
“The VeriSeq™ NIPT Solution offers a rapid workflow and
unprecedented automation that revolutionizes NIPT. With this validated,
CE-IVD marked solution featuring CE-IVD library prep and analysis
software, customers can now access highly reliable NGS-based NIPT in
their own labs,” said
The VeriSeq™ NIPT Solution is available for order and is now shipping. For more information, visit www.illumina.com/VeriSeqNIPTEU.
About Illumina, Inc.
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.
This release contains forward-looking statements that involve risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements we make regarding the expected availability dates for new products and services and FDA submission dates and intentions for certain products and services. Important factors that could cause actual results to differ materially from those in any forward-looking statements include challenges inherent in developing, manufacturing, and launching new products and services, and the other factors that are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.